Cargando…

High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate

BACKGROUND: Dysfunctional high-density lipoprotein (HDL) may have pro-inflammatory effects on the endothelial cells,which causes atherosclerosis in type 2 diabetes mellitus (T2DM). HDL is a major carrier of sphingosine-1-phosphate (S1P) in plasma while S1P exhibits multiple biological activities. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Xunliang, Peng, Hui, Liu, Donghui, Ji, Liang, Niu, Chenguang, Ren, Jun, Pan, Bing, Hu, Jianying, Zheng, Lemin, Huang, Yining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599898/
https://www.ncbi.nlm.nih.gov/pubmed/23360427
http://dx.doi.org/10.1186/1475-2840-12-27
_version_ 1782475555535323136
author Tong, Xunliang
Peng, Hui
Liu, Donghui
Ji, Liang
Niu, Chenguang
Ren, Jun
Pan, Bing
Hu, Jianying
Zheng, Lemin
Huang, Yining
author_facet Tong, Xunliang
Peng, Hui
Liu, Donghui
Ji, Liang
Niu, Chenguang
Ren, Jun
Pan, Bing
Hu, Jianying
Zheng, Lemin
Huang, Yining
author_sort Tong, Xunliang
collection PubMed
description BACKGROUND: Dysfunctional high-density lipoprotein (HDL) may have pro-inflammatory effects on the endothelial cells,which causes atherosclerosis in type 2 diabetes mellitus (T2DM). HDL is a major carrier of sphingosine-1-phosphate (S1P) in plasma while S1P exhibits multiple biological activities. However, potential role of HDL and S1P in T2DM remains unexplored. We hypothesized that diabetic HDL with higher contents of S1P exerts beneficial effects on the vascular system. METHODS: Subjects with T2DM with or without proved large arteries atherosclerosis and normal controls (n=15 for each group) were recruited in the present study. HDL was isolated from the subjects by ultracentrifugation. The levels of HDL-associated S1P were determined by UPLC-MS/MS. The protective function of diabetic HDL and S1P was evaluated by measuring cyclooxygenase-2 (COX-2) expression and prostacyclin I-2 (PGI-2) release by human umbilical vein endothelial cells (HUVECs) using western blot and enzyme-linked immunosorbent assay (ELISA), respectively. RESULTS: The S1P levels in isolated HDL were significantly increased in T2DM subjects compared with controls (235.6 ± 13.4 vs 195.0 ± 6.4 ng/mg, P< 0.05). The diabetic HDL exerted greater protective effects on inducing COX-2 expression and PGI-2 release by HUVECs than those of control HDL (p < 0.05, p < 0.01, respectively). Pertussis toxin, a common inhibitor of G-couple protein receptors, and VPC 23019, an antagonist of S1P receptor 1 and 3 significantly attenuated HDL-induced COX-2 expression and PGI-2 release. CONCLUSIONS: Diabetic HDL carries higher level of S1P compared with normal HDL, which has the potential to contribute to protective effects on endothelial cells by inducing COX-2 expression and PGI-2 release. These findings provide a new insight of S1P function in T2DM patients, possibly leading to a new therapeutic target.
format Online
Article
Text
id pubmed-3599898
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35998982013-03-17 High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate Tong, Xunliang Peng, Hui Liu, Donghui Ji, Liang Niu, Chenguang Ren, Jun Pan, Bing Hu, Jianying Zheng, Lemin Huang, Yining Cardiovasc Diabetol Original Investigation BACKGROUND: Dysfunctional high-density lipoprotein (HDL) may have pro-inflammatory effects on the endothelial cells,which causes atherosclerosis in type 2 diabetes mellitus (T2DM). HDL is a major carrier of sphingosine-1-phosphate (S1P) in plasma while S1P exhibits multiple biological activities. However, potential role of HDL and S1P in T2DM remains unexplored. We hypothesized that diabetic HDL with higher contents of S1P exerts beneficial effects on the vascular system. METHODS: Subjects with T2DM with or without proved large arteries atherosclerosis and normal controls (n=15 for each group) were recruited in the present study. HDL was isolated from the subjects by ultracentrifugation. The levels of HDL-associated S1P were determined by UPLC-MS/MS. The protective function of diabetic HDL and S1P was evaluated by measuring cyclooxygenase-2 (COX-2) expression and prostacyclin I-2 (PGI-2) release by human umbilical vein endothelial cells (HUVECs) using western blot and enzyme-linked immunosorbent assay (ELISA), respectively. RESULTS: The S1P levels in isolated HDL were significantly increased in T2DM subjects compared with controls (235.6 ± 13.4 vs 195.0 ± 6.4 ng/mg, P< 0.05). The diabetic HDL exerted greater protective effects on inducing COX-2 expression and PGI-2 release by HUVECs than those of control HDL (p < 0.05, p < 0.01, respectively). Pertussis toxin, a common inhibitor of G-couple protein receptors, and VPC 23019, an antagonist of S1P receptor 1 and 3 significantly attenuated HDL-induced COX-2 expression and PGI-2 release. CONCLUSIONS: Diabetic HDL carries higher level of S1P compared with normal HDL, which has the potential to contribute to protective effects on endothelial cells by inducing COX-2 expression and PGI-2 release. These findings provide a new insight of S1P function in T2DM patients, possibly leading to a new therapeutic target. BioMed Central 2013-01-30 /pmc/articles/PMC3599898/ /pubmed/23360427 http://dx.doi.org/10.1186/1475-2840-12-27 Text en Copyright ©2013 Tong et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Tong, Xunliang
Peng, Hui
Liu, Donghui
Ji, Liang
Niu, Chenguang
Ren, Jun
Pan, Bing
Hu, Jianying
Zheng, Lemin
Huang, Yining
High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title_full High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title_fullStr High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title_full_unstemmed High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title_short High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate
title_sort high-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin i-2 release in endothelial cells: relationship with hdl-associated sphingosine-1-phosphate
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599898/
https://www.ncbi.nlm.nih.gov/pubmed/23360427
http://dx.doi.org/10.1186/1475-2840-12-27
work_keys_str_mv AT tongxunliang highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT penghui highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT liudonghui highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT jiliang highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT niuchenguang highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT renjun highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT panbing highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT hujianying highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT zhenglemin highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate
AT huangyining highdensitylipoproteinofpatientswithtype2diabetesmellitusupregulatescyclooxgenase2expressionandprostacyclini2releaseinendothelialcellsrelationshipwithhdlassociatedsphingosine1phosphate